| Autor: |
Hélène Labrosse, Pierre-Paul Bringuier, Muriel Rogasik, Philippe Brun, Pierre-Jean Souquet, P. Bombaron, Camille Schiffler, Véronique Haddad, Sylvie Lantuejoul, Fadila Farsi, Chantal Decroisette, Pierre Fournel, Florence de Fraipont, Denis Moro-Sibilot, Isabelle Ray-Coquard, Fabien Forest, Yohan Fayet, Maurice Pérol, Sylvie Chabaud, Aurélie Swalduz, Michel Peoc'h |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Future Oncology. 15:2139-2149 |
| ISSN: |
1744-8301
1479-6694 |
| Popis: |
Aim: We performed a clinical audit of the management of patients with EGFR mutations, 1 year after the introduction of EGFR tyrosine kinase inhibitor ( EGFR-TKI) in first-line treatment. Methods: Compliance was defined by tumor molecular profiling for stage IIIB and IV non-small-cell lung cancer and first-line treatment as recommended by the French guidelines. Results: Among the 169 EGFR-mutated patients, compliance was 76.4%. The most common noncompliance criterion was chemotherapy given in first-line treatment instead of EGFR-TKI. No dedicated multidisciplinary meeting and type of institutions were independent unfavorable predictors for compliance. Compliance to guidelines was significantly correlated with time-to-first subsequent treatment improvement (2.5 vs 9.1 months; p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
